San Diego, CA – October 26th, 2009 – Avineuro Pharmaceuticals, Inc. reported today clinical Phase I results on AVN-101, a potent small molecule for treatment of Alzheimer’s disease. AVN-101 was well tolerated in a wide range of doses and no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-101 in Alzheimer’s disease in Q1 2010.

About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Contact:
Yan Lavrovsky, M.D., Ph.D.
CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive
San Diego, CA 92121
Phone: (858) 436-1537
Fax: (858) 228-9798
E-mail: ylavrovsky@avineuro.com
www.avineuro.com